Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.90
-1.06 (-5.06%)
Feb 21, 2025, 4:00 PM EST - Market closed
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 609 employees as of September 30, 2024. The number of employees increased by 84 or 16.00% compared to the previous year.
Employees
609
Change (1Y)
84
Growth (1Y)
16.00%
Revenue / Employee
$4,105
Profits / Employee
-$1,050,433
Market Cap
2.51B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ARWR News
- 3 days ago - Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions - Seeking Alpha
- 4 days ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 11 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Business Wire
- 12 days ago - Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire
- 4 weeks ago - Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 - PRNewsWire
- 4 weeks ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire